

Alexandre Wagner Silva Souza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1284030/publications.pdf>

Version: 2024-02-01

70
papers

2,065
citations

279487

23
h-index

253896

43
g-index

73
all docs

73
docs citations

73
times ranked

2648
citing authors

#	ARTICLE	IF	CITATIONS
1	Is positron emission tomography/magnetic resonance imaging a reliable tool for detecting vascular activity in treated childhood-onset Takayasu's arteritis? A multicentre study. <i>Rheumatology</i> , 2022, 61, 554-562.	0.9	3
2	The assessment of presenteeism and activity impairment in Behçet's syndrome and recurrent aphthous stomatitis: a multicentre study. <i>Rheumatology</i> , 2022, 61, 1538-1547.	0.9	6
3	Different epidemiologic profiles of systemic vasculitis between Brazil and Peru preliminary results in two referral centers from both countries. <i>Clinical Rheumatology</i> , 2022, 41, 635-639.	1.0	4
4	Targeting macrophages in systemic diseases. , 2022, , 279-302.		0
5	Increased modifiable cardiovascular risk factors in patients with Takayasu arteritis: a multicenter cross-sectional study. <i>Advances in Rheumatology</i> , 2021, 61, 1.	0.8	3
6	Editorial: Autoimmune Vasculitis - Advances in Pathogenesis and Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 720257.	2.2	1
7	Distribution of monocytes subpopulations in the peripheral blood from patients with Behçet's disease - Impact of disease status and colchicine use. <i>Clinical Immunology</i> , 2021, 231, 108854.	1.4	6
8	Lower serum levels of transforming growth factor- β 1 and disease activity in Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 161-162.	0.6	2
9	Epidemiologic Features of Systemic Vasculitides in the Southeast Region of Brazil. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S106-S110.	0.5	9
10	Diagnostic power and clinical impact of exome sequencing in a cohort of 500 patients with rare diseases. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 955-964.	0.7	22
11	Understanding Behçet's Disease in the Context of Innate Immunity Activation. <i>Frontiers in Immunology</i> , 2020, 11, 586558.	2.2	18
12	A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?. <i>Rheumatology International</i> , 2020, 40, 1123-1131.	1.5	14
13	Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 384-393.	1.1	12
14	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
15	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
16	HLA-B*51 and its main subtypes in Brazilian patients with Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 53-59.	0.4	0
17	Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese language. <i>Advances in Rheumatology</i> , 2019, 59, 43.	0.8	14
18	Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients. <i>Annals of Hepatology</i> , 2019, 18, 685-692.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Transcranial Doppler findings in antiphospholipid syndrome. <i>Lupus</i> , 2019, 28, 483-491.	0.8	3
20	Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis. <i>Advances in Rheumatology</i> , 2018, 58, 24.	0.8	2
21	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414.	0.8	49
22	Silent arterial inflammation during the apparent remission state of Takayasu's arteritis. What do cytokines tell us?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 33-39.	0.4	4
23	Central nervous system vasculitis in adults: An update. <i>Autoimmunity Reviews</i> , 2017, 16, 123-131.	2.5	45
24	Clinical interventions for Takayasu arteritis: A systematic review. <i>International Journal of Clinical Practice</i> , 2017, 71, e12993.	0.8	7
25	Recomendações da Sociedade Brasileira de Reumatologia para a terapia de indução para vasculite associada a ANCA. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 484-496.	0.8	12
26	Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. <i>Revista Brasileira De Reumatologia</i> , 2017, 57, 484-496.	0.7	11
27	Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?. <i>Autoimmunity Reviews</i> , 2017, 16, 1071-1078.	2.5	54
28	Cutaneous Vasculitis in a Patient with Crohn's Disease Treated with Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E1-E2.	0.9	16
29	M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis. <i>Arthritis Research and Therapy</i> , 2017, 19, 100.	1.6	22
30	Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. <i>Clinical Rheumatology</i> , 2017, 36, 205-208.	1.0	18
31	Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet's disease. <i>Arthritis Research and Therapy</i> , 2017, 19, 235.	1.6	43
32	CD4+ T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response?. <i>Clinical and Experimental Immunology</i> , 2017, 191, 50-59.	1.1	27
33	¹⁸ F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 299-308.	0.7	8
34	Leflunomide in Takayasu arteritis – A long term observational study. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 371-375.	0.7	23
35	Leflunomida na arterite de Takayasu – Estudo observacional de longo prazo. <i>Revista Brasileira De Reumatologia</i> , 2016, 56, 371-375.	0.8	39
36	Search for Autoantibodies in Systemic Vasculitis: Is It Useful?. , 2016, , 29-41.		0

#	ARTICLE	IF	CITATIONS
37	High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. <i>Arthritis Research and Therapy</i> , 2015, 17, 158.	1.6	10
38	High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations. <i>Rheumatology</i> , 2015, 54, kev202.	0.9	10
39	Emerging role of high mobility group box 1 in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2015, 14, 1057-1065.	2.5	27
40	Autoantibodies in Systemic Vasculitis. <i>Frontiers in Immunology</i> , 2015, 6, 184.	2.2	22
41	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.5	220
42	Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis. <i>PLoS ONE</i> , 2014, 9, e96067.	1.1	15
43	Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?. <i>Clinical and Experimental Immunology</i> , 2014, 178, 270-278.	1.1	18
44	Cryopyrin associated periodic syndrome with neurological involvement in a 50-year-old patient. <i>European Journal of Neurology</i> , 2014, 21, e27-8.	1.7	5
45	Diagnostic and classification criteria of Takayasu arteritis. <i>Journal of Autoimmunity</i> , 2014, 48-49, 79-83.	3.0	173
46	Retinal angiography and colour Doppler of retrobulbar vessels in Takayasu arteritis. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, 80-86.	0.4	11
47	Cognitive impairment in Brazilian patients with Behçet's disease occurs independently of neurologic manifestation. <i>Journal of the Neurological Sciences</i> , 2013, 327, 1-5.	0.3	17
48	L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis?. <i>Presse Medicale</i> , 2013, 42, 499-503.	0.8	3
49	Homocysteine Levels in Takayasu Arteritis – A Risk Factor for Arterial Ischemic Events. <i>Journal of Rheumatology</i> , 2013, 40, 303-308.	1.0	10
50	Is serum HMGB1 a biomarker in ANCA-associated vasculitis?. <i>Arthritis Research and Therapy</i> , 2013, 15, R104.	1.6	33
51	Giant cell arteritis: a multicenter observational study in Brazil. <i>Clinics</i> , 2013, 68, 317-322.	0.6	36
52	HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. <i>Autoimmunity Reviews</i> , 2012, 11, 909-917.	2.5	120
53	Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 227-230.	0.6	71
54	Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. <i>Rheumatology International</i> , 2012, 32, 703-709.	1.5	38

#	ARTICLE	IF	CITATIONS
55	Atypical manifestations in Brazilian patients with neuro-Behçet's disease. <i>Journal of Neurology</i> , 2012, 259, 1159-1165.	1.8	24
56	Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases. <i>European Journal of Neurology</i> , 2012, 19, 248-252.	1.7	18
57	Epilepsy and Behçet's disease: Cortical and hippocampal involvement in Brazilian patients. <i>Journal of the Neurological Sciences</i> , 2011, 309, 1-4.	0.3	11
58	Behçet Disease. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 416-420.	0.5	20
59	HELLP Syndrome and Its Relationship with Antiphospholipid Syndrome and Antiphospholipid Antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 517-523.	1.6	57
60	Lidocaine for systemic sclerosis: a double-blind randomized clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 5.	1.2	11
61	Sistema imunitário - parte II: fundamentos da resposta imunológica mediada por linfócitos T e B. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 552-580.	0.8	21
62	Antiplatelet Therapy for the Prevention of Arterial Ischemic Events in Takayasu Arteritis. <i>Circulation Journal</i> , 2010, 74, 1236-1241.	0.7	104
63	Sistema imunitário: Parte I. Fundamentos da imunidade inata com ênfase nos mecanismos moleculares e celulares da resposta inflamatória. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 434-447.	0.8	81
64	Association of anti-glomerular basement membrane antibody disease with dermatomyositis and psoriasis: case report. <i>Sao Paulo Medical Journal</i> , 2010, 128, 306-308.	0.4	10
65	Sistema imunitário: parte III. O delicado equilíbrio do sistema imunológico entre os polos de tolerância e autoimunidade. <i>Revista Brasileira De Reumatologia</i> , 2010, 50, 665-679.	0.8	13
66	Avaliação da pesquisa de anticorpos antifosfolípidos para o diagnóstico da síndrome antifosfolípide. <i>Revista Brasileira De Reumatologia</i> , 2009, 49, .	0.8	1
67	Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients. <i>Clinical Rheumatology</i> , 2009, 28, 379-383.	1.0	22
68	Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. <i>Lupus</i> , 2007, 16, 782-787.	0.8	32
69	Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. <i>Sao Paulo Medical Journal</i> , 2005, 123, 137-142.	0.4	28
70	Female gout: clinical and laboratory features. <i>Journal of Rheumatology</i> , 2005, 32, 2186-8.	1.0	47